Induction of cell proliferation by the EGF/EGFR and the TGFα/EGFR axis in HNSCC [78,79] suggested a therapeutic potential for its inhibition using antagonistic monoclonal antibodies [80,81]. Here, EGFR is linked to head and neck squamous cell carcinoma.